LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment option in peripheral arterial disease

In.Pact Admiral

Medtronic added to its robust body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease.

The new data presented at the Leipzig Interventional Course (LINC) in Leipzig, Germany, included the two-year results from the MDT-2113 study (IN.PACT SFA Japan) and data from a critical limb ischaemia subgroup analysis from the IN.PACT Global study.

Two-year Japan data

New data from the IN.PACT SFA Japan Study were presented by Osamu Lida, Kansai Rosai Hospital, Japan. The study enrolled 100 patients across 11 sites in Japan and randomised treatment to either drug-coated balloon (n=68) or percutaneous transluminal angioplasty (n=32). The results were consistent with two-year findings from the pivotal IN.PACT SFA study, showing a low clinically-driven target lesion revascularisation (CD-TLR) rate and high patency rate.

“Across superficial femoral artery trials, IN.PACT Admiral has consistently demonstrated superior safety and efficacy compared to percutaneous transluminal angioplasty,” said Lida. “We are pleased to see comparable results in Japan at two-years with durable patency outcomes, low target lesion revascularisation, and no instances of thrombosis. There has been a critical unmet need in Japan for new technologies that safely and effectively treat peripheral arterial disease, and we believe IN.PACT Admiral is well-positioned to meet this need.”

IN.PACT Admiral SFA Japan demonstrated 79.8% primary patency in the drug-coated balloon group as compared to 46.9% in the plain balloon angioplasty group at two years based on Kaplan-Meier Estimate (p<0.001). The two-year results also demonstrated a CD-TLR rate of 9.1% for the drug-coated balloon group compared to 20.7% in the plain balloon angioplasty group (p=0.177) and a freedom from CD-TLR based on Kaplan-Meier estimate of 90.8 for the DCB group compared to 81.3 percent in the PTA group (p=0.114). In IN.PACT SFA Japan, major adverse events were also lower for the DCB at two years (15.2 percent compared to 24.1 percent in the PTA group; p=0.384), with no major target limb amputations. There were no additional safety concerns at two years.

Medtronic’s announcement follows the recent approval of IN.PACT Admiral from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of peripheral artery disease in the upper leg, specifically, in the superficial femoral arteries) and behind the knee (popliteal arteries). The MHLW also granted reimbursement approval for the IN.PACT Admiral in December of 2017. IN.PACT Admiral is expected to commercially launch in Japan after completing the conditions associated with Shonin approval.

Critical limb ischaemia cohort analysis

Michel Reijnen, vascular surgeon, Rijnstate Hospital, The Netherlands, presented the one-year results from the critical limb ischaemia subset of the IN.PACT Global Study, including data from 156 patients with Rutherford classification categories four and five. IN.PACT Admiral demonstrated consistent treatment effect among this group of patients. Data showed comparable effectiveness with a freedom from CD-TLR based on Kaplan-Meier Estimate of 86.6% (Rutherford category four) and 85.5% (in Rutherford category five) (p=0.6881). The rate of major target limb amputations remained low at 1.4% overall. Additionally, IN.PACT Admiral had a clear impact on improved quality of life as measured by the EQ-5D from baseline to 12 months (p<0.001).

“The treatment of critical limb ischaemia in peripheral arterial disease remains a challenge and has led to the need for more clinical evidence around the safety and efficacy of drug-coated balloon in this population,” said Reijnen. “The data presented are very encouraging in that we were able to confirm IN.PACT Admiral’s strong performance in this clinically complex patient subset, as well as improved quality of life.”


Please enter your comment!
Please enter your name here